To assess how missed screenings might affect cancer mortality rates, the National Cancer Institute turned to Oguzhan Alagoz, a professor of industrial and systems engineering at the University of Wisconsin–Madison whose research involves modeling both cancer epidemiology and infectious diseases.
“The question is really interesting because it’s a combination of the two areas I work in,” Alagoz says. His first estimates, unveiled in a widely read editorial published in Science in June by NCI director Normal E. Sharpless, showed that missed screenings might result in 5,000 additional deaths in breast cancer alone over the next decade. A separate group, looking at missed colon cancer screenings, predicted another 5,000 deaths.
When Alagoz produced his breast cancer estimates early in the pandemic, he thought the numbers might not be truly representative. So he worked to refine them, using better data with three powerful cancer models that incorporated numerous factors related to breast cancer—such as delayed screening, treatment effectiveness and long-term survival rates—and the nuanced ways they intersect to affect mortality over time. “Everyone can tell you what will happen immediately, but it’s hard to say what’s going to happen in five or 10 years,” Alagoz says. “If there’s a huge increase in smoking, you’re not going to see more lung cancer right away. You’re going to see that 10 or 15 years down the road.”
